

Subject Index

- Acetyl-L-carnitine (ALCAR), 443**
 acetylcholine release in rats pretreated with, 92-93
 effects of
 on pineal activity, 259
 on pituitary-adrenocortical activity, 256-257
Acetylcholine (ACh) release in rats pretreated with acetyl-L-carnitine, 92-93
Acetylcholinesterase activity in the brain, 107
 α_1 -Acid glycoprotein (AGP) mRNA levels, effect of aging on, 69
ACh, *see* Acetylcholine
Acute phase response, definition of, 73-74
Adaptive system, age-dependent alterations in, 388-389
Adaptive-longevity related process theory of caloric restriction, 370-371
Adrenocortical activity as marker of senescence, 257
AF-DX 116, *see* Muscarinic antagonists
Afferent terminals, 444
Aging
 band 3, 185-186
 cellular, models for, 186-188
 definition of, 401-402
 dysdifferentiation hypothesis of, 13, 17
 effect on
 α_1 -acid glycoprotein mRNA levels, 69
 α_1 -antitrypsin mRNA levels, 68-69
 albumin mRNA levels, 70-71
 T-kininogen mRNA levels, 73
 energy system alterations with, 391-392
 free radical theory of, 348-350
 glucocorticoid cascade hypothesis of, 346-347
 glycation theory of, 347-348
 histone variants and, 44-49
 I-compounds and, 376-377
 intrinsic, and aberrations in proliferative homeostasis, 402-403
 metabolic rate and, 344, 366-368
 mRNA as regulatory sites affected by, 72-73
 multistep model of cancer and, 14
 ontogenetic model of, 396-399
 reproductive, 168-170
 reproductive system alterations in, 386-388
 synaptic plasticity and, 99-102
 thymus, the clock of immunological, 165-168
 vs senescence, 444
 zinc turnover in, 315-316
Aging brain
 morphometric investigation of, 105, 108-109
 neurochemical investigation of, 105-107
Aging clock, residence of, 444
AGP, *see* α_1 -Acid glycoprotein
Albumin mRNA levels, effect of aging on, 70-71
ALCAR, *see* Acetyl-L-carnitine
Alzheimer's disease patients, beta-endorphin and cholecystokinin in cultured peripheral blood mononuclear cells from, 177-178
Anabolism and catabolism, 445
Anatomical basis of learning, hypothesis concerning, 100
Aneugens, *see* Clastogens and aneugens
 α_1 -Antitrypsin (AT) mRNA levels, effect of aging on, 68-69
AT, *see* α_1 -Antitrypsin
Atropine, *see* Muscarinic antagonists
B cells, *see* Transient monoclonal gammopathies
B-cell malignancies, 418
Band 3 aging, 185-186
BE, *see* Beta-endorphin
Benign monoclonal gammopathy, *see also* Monoclonal gammopathies
 as proliferation of immunoglobulin, 419-420
 in mice, 419
 three-stage development of, 423
Beta-adrenoceptor density, changes in, 357-358
Beta-endorphin (BE), *see also* Alzheimer's disease patients, Down's syndrome patients, Thymus
 aging associated with increase in concentrations of, 177-178
 in cultured peripheral blood mononuclear cells, 177
BMG, *see* Benign monoclonal gammopathy
Body temperature changes after infusion of lymphokines in brain, 120

- Bone marrow cells, seeding of, onto thymic explants, 230-231
- Bone marrow myeloid progenitors and Thy1+ cells, 233-235
- Bone marrow thymocyte progenitors, 230
- Bovine serum albumin (BSA), used as antigen, 135-137, 149-150
- Brain stem vagal nuclei, calcitonin gene-related peptide thymic nerves derived from, 224
- Bretylium tosylate (BT), 443
as possible influence of cellular stimulatory events, 30
effect of, inhibited by ouabain and tetrodotoxin, 31
- BSA, *see* Bovine serum albumin
- C**/PI, *see* Cholesterol/phospholipids ratio
- Calcitonin gene-related peptide (CGRP), *see also* Brain stem vagal nuclei, Cortico-medullary junction
within the mouse thymus, 218-227
- Caloric overload, 445
- Caloric restriction (CR), *see also* Adaptive-longevity related process, DNA damage
sex-specific response delayed by, 364-365
- Carcinophilia and cancer, 393-395
- Carcinogenesis, *see also* Carcinophilia, Geroprotectors, I-compounds
multistage model of, 373-376
- Cardiomyocytes, effect of prostaglandin Bx on life span of, 269-270
- Castration, effect on thymus weight, 167
- Cell mutation
hypoxanthine phosphoribosyl transferase used in study of, 54
mouse model system for detection of, 54-56
shuttle vectors in study of, 54
- Cell mutations/alterations, 188-190
- Cell surface patterns, phenomenological description of, 23-30
- Cells, common features of, 444
- Cellular aging, models for, 186-188
- Centenarians, cellular defense mechanisms of, 434-436
- Central nervous system (CNS) potentialities for neural plasticity, 99
- Cerebellar glomerulus, investigation of, 100-102
- CGRP, *see* Calcitonin gene-related peptide
- Chemical messengers, nerve fibers, and the blood-brain barrier, 444
- Cholecystokinin (CCK), *see also* Alzheimer's disease patients, Down's syndrome patients, Thymus
aging associated with increase in concentrations of, 177-178
in cultured peripheral blood mononuclear cells, 177
- Cholesterol/phospholipids (C/PI) ratio, 285
- Chromosomal mutations, classification of, 403-404
- Clastogens and aneugens, environmental, 407-410
- CNS, *see* Central nervous system
- Cortico-medullary junction, small cells at the, immunoreactive for calcitonin gene-related peptide, 222
- CR, *see* Caloric restriction
- 4-DAMP**, *see* Muscarinic antagonists
- Death hormone, 445
- Delayed-type hypersensitivity (DTH) response, assessment of, 294
- Dentate gyrus supragranular layer, investigation of, 100-101
- Dietary restrictions (DR), *see also* Plasma free corticosterone
insulin secretory response in rats subjected to, 332-333
- Dihydroepiandrosterone (DHEA), 443
- DNA amplification, *see* Pathogenic mechanism
- DNA damage
and the etiology of cancer, 376-377
result of caloric restriction, 368-370
- Down's syndrome (DS), *see also* Zinc supplementation
and oxygen free radical production, 431-433
- Down's syndrome patients, beta-endorphin and cholecystokinin in cultured peripheral blood mononuclear cells from, 177-178
- DR, *see* Dietary restrictions
- DS, *see* Down's syndrome
- DTH, *see* Delayed-type hypersensitivity response
- Dysdifferentiation, 74
- Dysdifferentiation hypothesis of aging
definition of, 13
testing the, 17
- ECoG**, *see* Electrocortical activity
- Electrocortical (ECoG) activity after infusion of lymphokines in brain, 120, 125-132
- Energy system, age-dependent alterations in, 391-392
- EOD, *see* Every-other-day schedule
- Every-other-day (EOD) schedule of restricted feeding, *see also* Intermittent feeding, 353-355

Evolutionary survival and individual death, 444

Extinction of our species, 445

FCET, *see* Flow cytometric energy transfer measurement

Feedback loops between nervous and immune systems, 444

Flow cytometric energy transfer measurement (FCET), 33-34

Free radical theory of aging, 348-350

Geroprotectors, *see also* Phenformin carcinogenesis, influenced by, 377-378

Glucocorticoid cascade hypothesis of aging, 346-347

Glycation theory of aging, 347-348

Glycolytic pathway, turnover of, 105-107, 112

H-Ig, *see* Homogeneous immunoglobulin components

Heredity, *see* Longevity and heredity

Histone variants

age-related differences in, 44-49

classification of, 42

tissue-specific differences in, 42-44

HLA, *see* Human leucocyte antigens

Homogeneous immunoglobulin components (H-Ig), 418

Houseflies, effect of prostaglandin Bx on life span of, 268

HPRT, *see* Hypoxanthine phosphoribosyl transferase

Human leucocyte antigens (HLA)

association with survival, 80-87

B40 and DR5, 81-86

Hypoxanthine phosphoribosyl transferase (HPRT), *see* Cell mutation

I-compounds, role in carcinogenesis and aging, 376-377

IF, *see* Intermittent feeding

Ig, *see* Immunoglobulin

IL, *see* Interleukins

Immortality, 441

Immune function, *see* Lipoproteins

Immune functions and autoimmune diseases, 444

Immune system, *see* Nervous-neuroendocrine-immune interactions

Immunoglobulin (Ig), *see also* Benign

monoclonal gammopathy

producing clone, 419

Immunosenescence

characteristics of, 239

definition of, 143

Inguinal lymph nodes, inflammatory response of, 137, 139-140

Insulin secretory response, *see also* Dietary restrictions, Intermittent feeding, 329-335

Interleukins (IL)

intra-locus coeruleus administration of, 121-123, 124, 125

intracerebroventricular administration of, 121, 124, 125

intrahippocampal administration of, 123, 124-125

Intermittent feeding (IF), insulin secretory response in rats subjected to, 331

LHRH, *see* Luteinizing hormone-releasing hormone

Life expectancy, dependent on environmental hazards, 3

Life span

and life rhythms, 444

maximum, 444

maximum human, 380-382

Lipoproteins, role of, in immune function, 278-283

Liver plasma membranes, measurements on, 356-357

Longevity and heredity, 78-79

Longevity determinant gene hypothesis

definition of, 2

experimental results supporting, 21-23

predictions of, 8-9

Longevity equation, 367-368

Longevity genes, 86

Longevity-related processes (LRP), *see also* Adaptive-longevity related process

definition of, 363

LRP, *see* Longevity-related processes

Luteinizing hormone-releasing hormone

(LHRH), sexually organized response involving, 161-162, 168-170

Luteinizing hormone-releasing hormone (LHRH) receptors

in brain and gonads, 162

in thymus and spleen, 163-164

Lymphocytes from old and young, responses of, 34-36

Macroenvironment, influence on micro-environment, 445

Major noninfectious diseases, four models of pathogenesis of, 395-396

Malonyldialdehyde (MDA) as index of lipid peroxidation, 267-268

MDA, *see* Malonyldialdehyde

- Melatonin (Mel), *see also* Thyroid system, 443
 chronic night administration of
 to old mice, 296–297
 to young mice, 294–295
 ovarian tumors caused by, 294–295, 302
 Membrane depolarization, 444
 Membrane parameters of splenic lymphocytes, 355–356
 Metabolic rate and aging process, 344, 366–368
 Metenkephalin (M-Enk), 443
 Methionine-enkephalin (Met-Enk), immunorestorative functions of, 135–145
 MG, *see* Monoclonal gammopathies
 Monoclonal gammopathies (MG), *see also* Transient monoclonal gammopathies, 418
 four major categories of, 421–423
 Multistep model of cancer and aging, 14
 Muscarinic (M) antagonists: atropine, 4-DAMP, AF-DX 116, pirenzepine, 95
 Muscarinic (M) receptor M3 in the regulation of acetylcholine release, 95
- N**
 Nervous-neuroendocrine-immune interactions in old age, 322–323
 Neuroendocrine system, *see* Nervous-neuroendocrine-immune interactions
 Neuroimmunodulation (NIM), 442
- O**
 OFR, *see* Oxygen free radicals
 Ontogenetic model of aging, 396–399
 Oxygen free radicals (OFR), *see* Down's syndrome, Peripheral blood lymphocytes
- P**
 PAA, *see* Platelet associated antibodies
 Pancreatic islets, isolation of, 328
 Paramecia aurelia, prostaglandin Bx as UV shield for, 270–271
 Pathogenesis of senile dementia, 104–105
 Pathogenic mechanism, DNA amplification as, 410–411
 PBMC, *see* Peripheral blood mononuclear cells
 Peripheral blood lymphocytes (PBL), sensitivity to oxygen free radicals, 436
 Peripheral blood mononuclear cells (PBMC), *see* Alzheimer's disease patients, Beta-endorphin, Cholecystokinin, Down's syndrome patients, Phytohemagglutinin, Thymus
- Peripheral lymphoid tissues, *see* Thyl+ cells
 PGBx, *see* Prostaglandin Bx
 PHA, *see* Phytohemagglutinin
 Phenformin (PhF), 443
 geroprotecting and tumor-preventing influence of, 397
 Phospholipase A₂ (PLA₂) as a "death trigger," 272, 274
 Phytohemagglutinin (PHA), *see also* Transferrin receptors
 peripheral blood mononuclear cells stimulated by, 175–177
 T cells stimulated by, 31
 Pineal activity, effects of acetyl-L-carnitine on, 259
 Pineal, link with superchiasmatic nucleus, 444
 Pirenzepine, *see* Muscarinic antagonists
 Pituitary-adrenocortical activity, effects of acetyl-L-carnitine on, 256–257
 PLA₂, *see* Phospholipase A₂
 Plasma free corticosterone in antiaging actions of food restriction, 347
 Platelet associated antibodies (PAA), *see also* Schizophrenia and dementia
 determining presence of, 206–207
 Preventive medicine, 442
 Proliferative homeostasis, aberrations in and intrinsic aging, 402–403
 Prostaglandin Bx (PGBx), *see also* Cardiac myocytes, Houseflies, Paramecia aurelia
 as antioxidant and antiinflammatory agent, 265–267
 ProT-alpha, *see* Prothymosin-alpha
 Prothymosin-alpha (ProT-alpha), immunorestorative effect of, 148–155
- R**
 Reactive oxygen species
 genetic alterations caused by, 12–14
 testing the role of, 17–19
 Regulatory sites affected by aging, mRNA as, 72–73
 Reproductive aging, 168–170
 Reproductive system, age-dependent alterations in, 386–388
- S**
 SCA, *see* Senescent cell antigen
 Schizophrenia and dementia
 average life span of platelets in, 212
 levels of platelet associated antibodies (PAA) detected in, 214–215
 SDAT, *see* Senile dementia of the Alzheimer type

- Senescent cell antigen (SCA)
 molecular mapping of, 190-195
 present on nucleated cells, 184
SENIEUR protocol, 284-285
Senile dementia of the Alzheimer type (SDAT)
 attempts to define, 104, 114-115
 pathology of, 99-100
Sheep red blood cells (SRBC), used as antigen, 135-136, 149
Shuttle vectors, *see* Cell mutation
Splenic lymphocytes, *see* Membrane parameters
SRBC, *see* Sheep red blood cells
Stress, meaning of, 444
Stromboli cocktails, 442
Synaptic plasticity and aging, 99-102
- T** cells, *see* transient monoclonal gammopathies
T-kininogen mRNA levels, effect of aging on, 73
TF5, *see* Thymosin fraction 5
Thy1+ cells, *see also* Bone marrow myeloid progenitors
 in peripheral lymphoid tissues, 235
Thymic explants, *see* Bone marrow cells
Thymic hormone treatment, effect of, 240-247
Thymocyte progenitors, *see* Bone marrow thymocyte progenitors
Thymopentin (TP5), effects of, 249-251
Thymosin fraction 5 (TF5), effects of, 248
Thymulin (TYN), 443
Thymulin activity, measuring, 317-318
Thymus, *see also* Bone marrow thymocyte progenitors, Brain stem vagal nuclei, Calcitonin gene-related peptide, Castration, Luteinizing hormone-releasing hormone receptors, Zinc and peripheral blood mononuclear cells cholecystokinin and beta-endorphin changes, 178
 pineaal implantation into, 292, 296-297
 the clock of immunological aging, 165-168
Thyroid system, route of immunopotentiating effects of melatonin, 303-304
TP5, *see* Thymopentin
Transduction of signals, 444
Transferrin receptors expressed on phytohemagglutinin, 282-283
Transient monoclonal gammopathies (MG), indicators of T and B cell imbalance, 421
Turpentine, as inflammatory agent, 137, 140
Two-dimensional DNA typing
 genome coverage by, 59-64
 protocol for, 58
Two-dimensional pattern of lipid and protein elements in plasma membrane, 33
- V**ariable number of tandem repeats (VNTR), numbers present in the genome, 58, 61-62
VNTR, *see* Variable number of tandem repeats
- Z**inc (Zn), 443
 and thymus growth, 247
Zinc supplementation in Down's syndrome, 319
Zinc turnover in aging, 315-316